{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:07:44Z","timestamp":1767888464835,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.yebeh.2017.12.024","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T08:16:19Z","timestamp":1517645779000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Selim","family":"Benbadis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Schiemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyzeila","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Elmoufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Whitesides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.12.024_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0015","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in adult patients with partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in three pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/NDT.S512","article-title":"Topiramate in the treatment of partial and generalized epilepsy","volume":"3","author":"Faught","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1046\/j.1528-1157.2001.02101.x","article-title":"A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy","volume":"42","author":"Wong","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0050","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs\u2014rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0060","series-title":"Abstract no 1.219 presented at the 69th annual American Epilepsy Society meeting, Philadelphia, USA, 4\u20138 December 2015","article-title":"Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures","author":"Otoul","year":"2015"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0080","series-title":"Topiramate prescribing information","author":"Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.yebeh.2017.12.024_bb0085","series-title":"Lamictal precribing information","author":"Food and Drug Administration","year":"2010"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017307874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017307874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T06:31:27Z","timestamp":1535092287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017307874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":17,"alternative-id":["S1525505017307874"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.12.024","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 UCB, Brussels, Belgium. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}